Granted Patent
B2
US 12,280,045 · App. 16/645,315 · Granted Apr 22, 2025
Antitumor agent and antitumor effect potentiator
Assignee:
TAIHO PHARMACEUTICAL CO., LTD.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention is intended to provide a novel antitumor agent that shows marked antitumor effects with reduced side effects. The present invention relates to an antitumor agent characterized by coadministration of an acyl thiourea compound represented by general formula (I) or a salt thereof, and an immune checkpoint molecule regulator.
Claims (6)
1. A method of treating a malignant tumor selected from the group consisting of melanoma, kidney cancer, lung cancer, head and neck cancer, Hodgkin's lymphoma, bladder cancer, colon cancer, liver cancer, stomach cancer, osteosarcoma and soft tissue sarcoma, breast cancer, and prostate cancer comprising coadministration 4-(2-fluoro-4-(3-(2-phenylacetyl) thioureido) phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide or a salt thereof, and an immune checkpoint molecule regulator comprising an anti-PD-1 antibody.
2. The method of claim 1 ,
wherein the anti-PD-1 antibody is at least one of nivolumab and pembrolizumab and the malignant tumor is colon cancer.
3. The method of claim 1 ,
wherein a target cancer is at least one selected from, colon cancer, osteosarcoma and soft tissue sarcoma, and breast cancer.
4. The method of claim 1 wherein the anti-PD-1 antibody is at least one of nivolumab and pembrolizumab and a target cancer is at least one selected from, colon cancer, osteosarcoma and soft tissue sarcoma, and breast cancer.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 6, 2020
From: HARUMA, TOMONORI
To: TAIHO PHARMACEUTICAL CO., LTD.
Reel/Frame 052041/0454 →
Priority Claims (1)
JP 2017-173352
· Sep 8, 2017
· national
Continuity (1)
References Cited (256)
US 5254541A
· Kwong
· 1993
[cited by applicant]
US 7135466B2
· Sakai et al.
· 2006
[cited by applicant]
US 7253286B2
· Funahashi et al.
· 2007
[cited by applicant]
US 7425564B2
· Fujiwara et al.
· 2008
[cited by applicant]
US 7579473B2
· Bannen et al.
· 2009
[cited by applicant]
US 8304427B2
· Suda
· 2012
[cited by examiner]
US 9149471B2
· Miyaura et al.
· 2015
[cited by applicant]
US 20040246603A1
· Rydqvist
· 2004
[cited by applicant]
US 20050113284A1
· Nakamura et al.
· 2005
[cited by applicant]
US 20060160832A1
· Funahashi et al.
· 2006
[cited by applicant]
US 20080161305A1
· Forsyth et al.
· 2008
[cited by applicant]
US 20080312221A1
· Fujiwara et al.
· 2008
[cited by applicant]
US 20090226443A1
· Filvaroff et al.
· 2009
[cited by applicant]
US 20090274693A1
· Gilmer et al.
· 2009
[cited by applicant]
US 20100324087A1
· Yamamoto
· 2010
[cited by applicant]
US 20100297075A1
· Chan et al.
· 2010
[cited by applicant]
US 20110104161A1
· Burgess et al.
· 2011
[cited by applicant]
US 20130142790A1
· Gilmer et al.
· 2013
[cited by applicant]
US 20130150363A1
· Gilmer et al.
· 2013
[cited by applicant]
US 20140378409A1
· Fujita et al.
· 2014
[cited by applicant]
US 20150056207A1
· Filvaroff et al.
· 2015
[cited by applicant]
US 20150133449A1
· Muthuppalaniappan et al.
· 2015
[cited by applicant]
US 20170088626A1
· Jure-Kunkel et al.
· 2017
[cited by applicant]
US 20190263923A1
· Jure-Kunkel et al.
· 2019
[cited by applicant]
CN 1448053A
· 2003
[cited by applicant]
CN A101491240
· 2009
[cited by applicant]
CN A101926808
· 2010
[cited by applicant]
CN A105377235
· 2016
[cited by applicant]
CN 106551911A
· 2017
[cited by applicant]
EP 1411046A1
· 2004
[cited by applicant]
EP 1466624A1
· 2004
[cited by applicant]
EP 2287155A1
· 2011
[cited by applicant]
JP 5238958A
· 1993
[cited by applicant]
JP 2003238592A
· 2003
[cited by applicant]
JP 2005272474A
· 2005
[cited by applicant]
JP 2008504366T
· 2008
[cited by applicant]
JP 2009518296A
· 2009
[cited by applicant]
JP 2011500778A
· 2011
[cited by applicant]
JP 20124860609B2
· 2012
[cited by applicant]
JP 2013518887A
· 2013
[cited by applicant]
JP 2013529207A
· 2013
[cited by applicant]
JP 2016196411A
· 2016
[cited by applicant]
JP 2017507155A
· 2017
[cited by applicant]
KR 1020040030690A
· 2004
[cited by applicant]
KR 1020100132023A
· 2010
[cited by applicant]
RU 20132494470C1
· 2013
[cited by applicant]
RU 2589713C2
· 2016
[cited by applicant]
WO WO0147890A1
· 2001
[cited by applicant]
WO WO03000660A1
· 2003
[cited by applicant]
WO WO2005030140A1
· 2005
[cited by applicant]
WO WO2005082855A1
· 2005
[cited by applicant]
WO WO2005121125A1
· 2005
[cited by applicant]
WO WO2006004636A2
· 2006
[cited by applicant]
WO WO2006004833A2
· 2006
[cited by applicant]
WO WO2006004884A2
· 2006
[cited by applicant]
WO WO2006104161A1
· 2006
[cited by applicant]
WO WO2006108059A1
· 2006
[cited by applicant]
WO WO2007064797A2
· 2007
[cited by applicant]
WO WO2009053737A2
· 2009
[cited by applicant]
WO WO2009096377A1
· 2009
[cited by applicant]
WO WO2009125597A1
· 2009
[cited by applicant]
WO WO2009137429A1
· 2009
[cited by applicant]
WO WO2009140549A1
· 2009
[cited by applicant]
WO WO2010093789A2
· 2010
[cited by applicant]
WO WOA12010150127
· 2010
[cited by applicant]
WO WO2011145035A1
· 2011
[cited by applicant]
WO WO2011162835A1
· 2011
[cited by applicant]
WO WO2013058303A1
· 2013
[cited by applicant]
WO WO2013100014A1
· 2013
[cited by applicant]
WO WO2015046484A1
· 2015
[cited by applicant]
WO WO2016090174A1
· 2016
[cited by applicant]
WO WO2016140717A1
· 2016
[cited by applicant]
WO WO2016175305A1
· 2016
[cited by applicant]
WO WO2016208744A1
· 2016
[cited by applicant]
WO WO2018151177A1
· 2018
[cited by applicant]
Miao, et al., Oncotarget 2017, vol. 8, No. 33 p. 53978-53988 (Year: 2017).
[cited by examiner]
Ott et al., Journal of Clinical Oncology 2017 vol. 35, No. 34, pp. 3823-3829; Published online Aug. 16, 2017 (Year: 2017).
[cited by examiner]
Overman, et al 2017., Lancet Oncology 2017 18:1182 (Year: 2017).
[cited by examiner]
Combined Russian Office Action and Search Report issued Feb. 15, 2021 in Russian Patent Application No. 2019125612 (with English translation of the Office Action), 15 pages.
[cited by applicant]
Handbook of Pharmaceutical Excipients, 6
[cited by applicant]
Arun, R., et al., “Cyclodextrins as Drug Carrier Molecule: A Review”, Scientia Pharmaceutica, 2008, vol. 76., pp. 567-598 URL: https://www.mdpi.com/2218-.
[cited by applicant]
Jantarat, C., et al., “Curcumin-Hydroxypropyl-β-Cyclodextrin Inclusion Complex Preparation Methods: Effect of Common Solvent Evaporation, Freeze Drying, and pH Shift on Solubility and Stability of Curcumin”, Trop J Phar…
[cited by applicant]
Alonso. E.C.P., et al., “Development of carvedilol-cyclodextrin inclusion complexes using fluid-bed granulation: a novel solid-state complexation alternative with technological advantages”, J Pharm Pharmacol., 2016, vol…
[cited by applicant]
Stringer J.L. Drug, in: Encyclopedia Britannica//website, URL: https://www.britannica.com/science/drug-chemical-agent.
[cited by applicant]
Extended European Search Report issued Apr. 30, 2021 in European Patent Application No. 18854415.9, 11 pages.
[cited by applicant]
Jin Zhang, et al., “Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs,” European Journal of Medicinal Chemistry, vol. 108, XP029383501, 2016, pp. 495-504.
[cited by applicant]
Office Action mailed on Nov. 4, 2020 in co-pending U.S. Appl. No. 16/485,971, 17 pages.
[cited by applicant]
U.S. Appl. No. 15/574,060, filed Nov. 14, 2017, US 2018-0289690 A1, Akio Fujioka.
[cited by applicant]
U.S. Appl. No. 12/937,312, filed Oct. 11, 2010, US 2011-0034439 A1, Yoshimitsu Suda et al.
[cited by applicant]
U.S. Appl. No. 15/570,021, filed Oct. 27, 2017, US 2018-0161317 A1, Ayako Sato.
[cited by applicant]
U.S. Appl. No. 14/369,060, filed Jun. 26, 2014, US 2014-0378409 A1, Hidenori Fujita.
[cited by applicant]
U.S. Appl. No. 16/485,971, filed Aug. 14, 2019, US 2020-0060973 A1, Shinji Okada.
[cited by applicant]
International Search Report and Written Opinion issued on Dec. 4, 2018, in PCT/JP2018/033108, 36 pages (with English translation).
[cited by applicant]
PLoS ONE, “High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells”, 11 (10): e0164830 (2016),…
[cited by applicant]
Cancer Cell, “Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy” 25: 846-859 (2014), 14 pages.
[cited by applicant]
Frontiers in Immunology, “Functional relationship between tumor-associated macrophages and macrophage colony- stimulating factor as contributors to cancer progression”, 5: Article 489 (2014), 15 pages.
[cited by applicant]
Cancers, “The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy”, 8 (10), 97: 8100097 (2016), 22 pages.
[cited by applicant]
Cancers, “The Receptor Tyrosine Kinase AXL in Cancer Progression”, 8 (11), 103: 8110103 (2016), 16 pages.
[cited by applicant]
Nat. Rev. Cancer, “The blockade of immune checkpoints in cancer immunotherapy”, 12 (4): 252-264 (2012), 31 pages.
[cited by applicant]
The New England Journal of Medicine, “Safety, Activity, and Immune Correlate of Anti-PD-1 Antibody in Cancer”, 366; 26: 2443-2454 (2012), 12 pages.
[cited by applicant]
Cell, “Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy”, 168 (4): 707-723 (2017), 17 pages.
[cited by applicant]
Science Translational Medicine, “In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy”, 9 (389): eaal 3604 (2017), 11 pages.
[cited by applicant]
International Search Report issued on May 1, 2018 in PCT/JP2018/005140, (with English translation), 5 pages.
[cited by applicant]
Opinion of the International Searching Authority issued on May 1, 2018 in PCT/JP2018/005140, (with English translation), 11 pages.
[cited by applicant]
Amin, A. et al., “Nivolumab (anti-PD-1 ; BMS-936558, ON0-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)”, Journal of Clinical Oncology, Jan. 2017, vol. 32,…
[cited by applicant]
Fujita, H, et al, “The Novel VEGF Receptor/MET-Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile”, Molecular Cancer Therapeutics, 2013, vol. 12, No. 12, pp. 2…
[cited by applicant]
Manegold, C. et al., “The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC”, Journal of Thoracic Oncology, Feb. 2017, vol. 12, No. 2, pp. 194-207.
[cited by applicant]
Lee, C-H. et al., “A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma.”, Annals of Oncology, Aug. 31, 2017, vol. 28, Supply. 5, pp. v295-v296.
[cited by applicant]
Kato Yu, “Combination mechanism of Lenvatinib with immune checkpoint inhibitor by cancer immunity regulation”, Japanese Society of Hepato-Biliary-Pancreatic Surgery, Aug. 2017, vol. 75, No. 2, pp. 473-477 (with English …
[cited by applicant]
Kato, Y. et al., “Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response.”, Annals of Oncology, 2016, vol. 27, Supply. 6, Abstract No. 2PD., ISSN 1569-8041.
[cited by applicant]
Nadal, R. et al., “Final results of a . . . in patients (pts) with metastatic urothelial carcirma (mUC) and other genitourinary (GU) malignancies.”, Annals of Oncology, Aug. 31, 2017, vol. 28, supply 5, p. v295.
[cited by applicant]
Davare, M. A. et al., “Structural Insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors”, PNAS, 2015, vol. 112, No. 39, pp. E5381-E5390.
[cited by applicant]
Bentzien, F. et al., “In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer”, Thyroid, 2013, vol. 23, No. 12, pp. 1569-1577.
[cited by applicant]
International Search Report issued Jun. 28, 2016, in PCT/JP2016/063413, 2 pages.
[cited by applicant]
Office Action mailed on Mar. 28, 2018 in co-pending U.S. Appl. No. 15/570,021, 6 pages.
[cited by applicant]
Notice of Allowance mailed on Jul. 26, 2018 in co-pending U.S. Appl. No. 15/570,021, 6 pages.
[cited by applicant]
International Search Report issued on May 19, 2009 in PCT/JP2009/01655, 2 pages.
[cited by applicant]
Extended European Search Report issued on Apr. 11, 2012 in Patent Application No. 09730440.6, 5 pages.
[cited by applicant]
Notice of Allowance mailed on Aug. 13, 2012 in co-pending U.S. Appl. No. 12/937,312, 9 pages.
[cited by applicant]
International Search Report Issued Feb. 12, 2013 in PCT/JP2012/083794, 3 pages.
[cited by applicant]
Written Opinion of the International Searching Authority issued Feb. 12, 2013 in PCT/JP2012/083794 filed Dec. 27, 2012, 8 pages.
[cited by applicant]
Office Action mailed on Sep. 24, 2015 in co-pending U.S. Appl. No. 14/369,060, 17 pages.
[cited by applicant]
Extended European Search Report issued on Apr. 28, 2015 in Patent Application No. 12863476.3, 8 pages.
[cited by applicant]
Office Action mailed on Apr. 22, 2016 in co-pending U.S. Appl. No. 14/369,060, 25 pages.
[cited by applicant]
Office Action mailed on Apr. 21, 2017 in co-pending U.S. Appl. No. 14/369,060, 29 pages.
[cited by applicant]
Office Action mailed on Nov. 30, 2017 in co-pending U.S. Appl. No. 14/369,060, 17 pages.
[cited by applicant]
Office Action mailed on Aug. 21, 2019 in co-pending U.S. Appl. No. 14/369,060, 19 pages.
[cited by applicant]
International Search Report issued Sep. 13, 2016 in PCT/JP2016/068902, 3 pages.
[cited by applicant]
Office Action mailed on Sep. 20, 2018 in co-pending U.S. Appl. No. 15/574,060, 8 pages.
[cited by applicant]
Extended European Search Report issued Jan. 30, 2019 in Patent Application No. 16814513.4, 8 pages.
[cited by applicant]
Notice of Allowance mailed on Jun. 17, 2019 in co-pending U.S. Appl. No. 15/574,060, 8 pages.
[cited by applicant]
“Poster Session—Met, Ret and Notch”, European Journal of Cancer, vol. 48, No. 6, Nov. 8, 2012, p. 94.
[cited by applicant]
Masako Yokoo, et al., “2-Hydroxypropyl-(3-Cyclodextrin Acts as a Novel Anticancer Agent”, PLOS ONE, vol. 10, No. 11, Nov. 4, 2015, pp. 1-20.
[cited by applicant]
Chisa Imamura, “Applied Technology of Cyclodextrin Popular Edition”, CMC Publishing Co., Ltd., 2013, pp. 253-261 (with partial English translation).
[cited by applicant]
Kazuhide Ashizawa, et al. “Polymorphic Phenomena of Drug and Science of Crystallization Development and Production and trend of Regulation”, Iyakuhin no Takei Gensho to Shoseki no Kagaku, 2002, 77 pages. (with English t…
[cited by applicant]
Mino R. Caira, “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry, vol. 198, 1998, pp. 163-208.
[cited by applicant]
Bradley D. Anderson, et al., “Preparation of Water-Soluble Organic Compounds Through Salt Formation”, (Edited by Wermuth, C.G), Saishin Soyaku Kagaku Last Volume, 1999, 65 pages (with English translation).
[cited by applicant]
Seto, T., “Trend of Molecular Target Therapy—from ASCO 201 O ASCO Report: Ling Cancer”. Cancer Molecular Target Therapy, vol. 8, No. 4, pp. 267-270, 2010 (with Partial English translation).
[cited by applicant]
Stephen M. Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, vol. 66, No. 1, Jan. 1977, pp. 1-19.
[cited by applicant]
James G. Christensen, et al., “c-Met as a Target for Human Cancer and Characterization of Inhibitors for Therapeutic El Intervention”, Cancer Letters, vol. 225, 2005, pp. 1-26.
[cited by applicant]
K. Michael Weidner, et al., “Scatter Factor: Molecular Characteristics and Effect on the Invasiveness of Epithelial Cells”, the EJ Journal of Cell Biology, vol. 111, Nov. 1990, pp. 2097-2108.
[cited by applicant]
Paolo M. Cornoglio, et al., “Scatter Factors and Invasive Growth”, Cancer Biology, vol. 11, 2001, pp. 153-165.
[cited by applicant]
Xiaohua Xin, et al., “Hepatocyte Growth Factor Enhances Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro EL and in Vivo”, American Journal Of Pathology, vol. 158, No. 3, Mar. 2001, pp. 1111-1120.
[cited by applicant]
Eiji Ichimura, et al., “Expression of c-met/HGF Receptor in Human Non-small Cell Lung Carcinomas in vitro and in vivo and EM Its Prognostic Significance”, JPN J. Cancer Res, vol. 87, Oct. 1996, pp. 1063-1069.
[cited by applicant]
Masakazu Nakajima, et al., “The Prognostic Significance of Amplification and Overexpression of c-met and c-erb B-2 in EN Human Gastric Carcinomas”, Cancer, vol. 85, No. 9, May 1, 1999, pp. 1894-1902.
[cited by applicant]
Wilfredo Hernandez, et al., “Synthesis, Characterization and Antitumor Activity of Copper (II) Complexes, [Cul
[cited by applicant]
Xiao-Ping Rao, et al., “Synthesis and Antitumor Activities of Unsymmetrically Disubstituted Acylthioureas Fused with EP Hydrophenanthrene Structure”, Medicinal Chemistry Research, vol. 20, 2011, pp. 333-338.
[cited by applicant]
Takahumi Nishii, et al., “c-Met Inhibitors Intensify the Sensitivity to Anticancer Agents of Gastric Cancer Stem Cell-Like SP EQ Cells”, Journal of Japan Society for Cancer Therapy, vol. 43, No. 2, 2008, p. 390, (with P…
[cited by applicant]
Sheng-Hua Chu, et al., “c-Met Antisense Oligodeoxynucleotides Increase Sensitivity of Human Glioma Cells to Paclitaxel”, Oncology Reports, vol. 24, No. 1, XP 009183704, Jul. 1, 2010, pp. 189-194.
[cited by applicant]
Isaiah J. Fidler, “Tumor Heterogeneity and the Biology of Cancer Invasion and Metastasis” Cancer Research, vol. 38, Sep. 1978, pp. 2651-2660.
[cited by applicant]
“Benign Tumors” Healthline Website, www.healthline.com/health/benign#overview1, Accessed Mar. 29, 2017, 6 pages.
[cited by applicant]
Stephen Neidle, “Cancer Drug Design and Discovery” Elsevier/Academic Press, 2008, pp. 427-431.
[cited by applicant]
P. Spagnolo, et al., “Idiopathic Pulmonary Fibrosis: Recent Advances on Pharmacological Therapy” Pharmacology & Therapeutics, 2015, 10 Pages.
[cited by applicant]
Richard Hubbard, et al., “Lung Cancer and Cryptogenic Fibrosing Alveolitis, A Population-Based Cohort Study” American Journal of Respiratory and Critical Care Medicine, vol. 161, 2000, pp. 5-8.
[cited by applicant]
David M. Spain, “The Association of Terminal Bronchiolar Carcinoma with Chronic Interstitial Inflammation and Fibrosis of the Lungs” Am Rev Tuberc, 1957, pp. 559-567.
[cited by applicant]
Arnab Datta, et al., “Novel Therapeutic Approaches for Pulmonary Fibrosis” British Journal of Pharmacology, vol. 163,2011, pp. 141-172.
[cited by applicant]
Lu Zhao, et al. “Paracrine Activation of MET Promotes Peritoneal Carcinomatosis in Scirrhous Gastric Cancer” Cancer Science, vol. 104, No. 12, XP002787868, Dec. 2013, pp. 1640-1646.
[cited by applicant]
Yano, S. et al., “Resistance to EGFR-TK Inhibitors Induced by HGF/MET Signaling”, Respiratory Medicine, vol. 17, No. 3, pp. 283-288, 201 O ( with Partial English translation).
[cited by applicant]
Korean Office Action issued Nov. 4, 2021 in Korean Patent Application No. 10-2020-7006381 (with English translation), 15 pages.
[cited by applicant]
Office Action issued in corresponding Chinese Appln. 201880012000.X issued on Jan. 25, 2022 (with partial English machine Translation).
[cited by applicant]
Biochemistry (No. 2016-2-013) (for food and related specialties), Thrones, pp. 32-33, China Light Industry Press, Jan. 2017—ISBN 978-7-5184-1040-8 (with English Translation).
[cited by applicant]
“Study on inclusion complexation of insoluble drugs with β-cyclodextrin and its derivatives”, Series I, Excellent High Paper of China, Full Database Engineering Technology, Part I (with English Translation).
[cited by applicant]
Office Action issued in corresponding Russian Appln 2020109716 issued on Feb. 15, 2022 (with English Translation).
[cited by applicant]
M.D.Mashkovskiy. Lekarstvennye sredstva (Medicinal Agents), 14th edition, vol. 1, Moscow, 2001, p. 11 (with partial English translation).
[cited by applicant]
U.S. Pat. No. 8,304,427 B2, Nov. 6, 2012, Yoshimitsu Suda, et al.
[cited by applicant]
U.S. Pat. No. 10,449,189 B2, Oct. 22, 2019, Akio Fujioka.
[cited by applicant]
U.S. Pat. No. 10,143,688 B2, Dec. 4, 2018, Ayako Sato.
[cited by applicant]
U.S. Appl. No. 14/369,060, filed Jun. 26, 2014, US 2014/0378409 A1, Hidenori Fujita, et al.
[cited by applicant]
U.S. Pat. No. 11,110,062 B2, Sep. 7, 2021, Shinji Okada.
[cited by applicant]
U.S. Appl. No. 17/347,989, filed Jun. 15, 2021, US 2021/0308056 A1, Shinji Okada.
[cited by applicant]
U.S. Appl. No. 16/645,315, filed Mar. 6, 2020, US 2021-0030738 A1, Tomonori Haruma.
[cited by applicant]
Lu Zhao, et al. “Paracrine Activation of MET Promotes Peritoneal Carcinomatosis 1n Scirrhous Gastric Cancer” Cancer Science, vol. 104, No. 12, XP002787868, Dec. 2013, pp. 1640-1646.
[cited by applicant]
Shukuya, T. et al. “Paradigm Shift from Non-Selective Treatment to Selective Treatment”, Mebio Oncology, vol. 6, No. 1, pp. 23-31, 2009 (with Partial English translation).
[cited by applicant]
Uenaka, T. et al “2. Current Status of Development of Molecular Therapeutic drugs Targeting HGF/c-Met”, Experimental Medicine, vol. 29, No. 2, pp. 303-309, 2011 (with Partial English translation).
[cited by applicant]
Yano, S. et al., “Resistance to EGFR-TK Inhibitors Induced by HGF/MET Signaling”, Respiratory Medicine, vol. 17, No. 3, pp. 283-288, 2010 (with Partial English translation).
[cited by applicant]
“Osteoporosis Prevention, Diagnosis and Therapy”, JAMA vol. 285, No. 6, pp. 785-794, Feb. 14, 2001.
[cited by applicant]
T.D. Rachner et al., “Osteoporosis: now and the future”, www.thelancet.com vol. 377, Apr. 9, 2011, pp. 1276-1287.
[cited by applicant]
M. Shiraki et al., Long-Term Treatment of Postmenopausal Osteoporosis with Active Vitamin 03, 1-Alpha-Hydroxycholecalciferol (1α-OHD
[cited by applicant]
R. Rizzoli et al., “Adverse Reaction and Drug-Drug Interactions in the Management of Woman with Postmenopausal Osteoporosis”, Calcif Tissue Int (2011), 89:91-104.
[cited by applicant]
“Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women”, JAMA. Jul. 17, 2002—vol. 288, No. 3, pp. 321-333.
[cited by applicant]
M.A. Bolognese. “SERMs and SERMs with estrogen for postmenopausal osteoporosis”, Rev. Endocr Metab Disord (2010) 11 :253-259.
[cited by applicant]
V Lim et al., “New therapeutic targets for osteoporosis: Beyond denosumab”, Maturitas 73 (2012), 269-272.
[cited by applicant]
S. Das et al, “Osteoporosis—a current view of pharmacological prevention and treatment”, Drug Design. Development and Therapy, 2013:7, pp. 435-448.
[cited by applicant]
E. Canalis, “New Treatment Modalities in Osteoporosis”, Endocrine Practice, vol. 16. No. 5, Sep./Oct. 2010, pp. 855-863.
[cited by applicant]
Combined Russian Federation Office Action and Search Report issued on Nov. 29, 2019 in Patent Application No. 2017145271 /04(077515) (with English translation).
[cited by applicant]
Notice of Reasons for Refusal issued Jan. 26, 2021 in Japanese Patent Application No. 2017-525457 (with English language translation).
[cited by applicant]
Hidenori Fujita, et al., “The Novel VEGF Receptor/MET-Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile,” Molecular Cancer Therapeutics, vol. 12, No. 12, Dec.…
[cited by applicant]
Takafumi Nishii, et al., “c-Met Inhibitor Might be a Promising Molecular-Targeted Molecule Against for CPT11-Resistant Cancer Stem Cells”, AACR Annual Meeting, XP 055182601, 2009, 2 pages.
[cited by applicant]
Office Action issued Jan. 28. 2021 in corresponding Korean Patent Application No. 10-2019-7023592 (with English Translation), 10 pages.
[cited by applicant]
Kyu Hyun Choi et al., “Hyaluronic acid gel formulation containing Piroxicam: Hydroxypropyl-β-cyclodextrin inclusion complex for intra-articular delivery” (with English abstract), Biomaterials Research 13 (1) : 1-6(2009)…
[cited by applicant]
George SJ et al., “Studies on the Preparation, Characterization, and Solubility of 2-HP-β-Cyclodextrin-Meclizine HCI Inclusion Complexes”, Journal of Young Pharmacists vol. 4 / No. 4, (2012). pp. 220-227.
[cited by applicant]
Office Action issued in corresponding Russian Application No. 2019125612 on Feb. 15, 2021 (with English Translation).
[cited by applicant]
Office Action issued in corresponding Russian Application 2019125612 on Jul. 6, 2021, with English Translation.
[cited by applicant]
Stringer J.L. Drug, in: Encyclopedia Britannica//website, URL: hllps://www.britannica.com/science/drug-chemical-agent.
[cited by applicant]
The Pursuit of Responsible Use of Medicines. Sharing and Learning from Country Experiences. Oct. 2, 2012, Technical document. WHO Reference WHO/EMP/MAR/2012.3. URL: https://www.who.int/publications/i/item/WHO-EMP-MAR-20…
[cited by applicant]
Notification of Reason for Refusal issued Nov. 4, 2021 in Korean Patent Application No. 10-2020-7006381 (with English language translation), 15 pages.
[cited by applicant]
Office Action mailed Sep. 30, 2021 in co-pending U.S. Appl. No. 16/645,315, 39 pages.
[cited by applicant]
Lulu Miao, et al., “PD-L1 and c-MET Expression and Survival in Patients with Small Cell Lung Cancer” Oncotarget, vol. 8, No. 33, 2017, pp. 53978-53988.
[cited by applicant]
Patrick A. Ott, et al. “Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study” Journal of Clinical Oncology, vol. 35, No. 34, Dec. 1, 2017, pp. 3823-3829 and …
[cited by applicant]
Steppeler F. et al., “Chiral Thioureas-Preparation and Significance in Asymmetric Synthesis and Medicinal Chemistry”, Molecules, Jan. 18, 2020, vol. 25, No. 2, Article No. 401, pp. 1 to 56, https://doi.org/10.3390/molec…
[cited by applicant]
Yamashita, Kazuko et al., “Development. of an On-line Sample Enrichment System Coupled to ESI-TOFMS—Challenge to highly sensitive structural elucidation of impurities of agrochemicals and pharmaceuticals-”, Sumitomo Che…
[cited by applicant]
Murakami, Tomonori et al., “Structure Elucidation of Impurities in Pharmaceuticals by HPLC Hyphenated Techniques”, Chromatography, 2012, vol. 33, No. 3, pp. 179-190 (with English Abstract).
[cited by applicant]
International Search Report issued in PCT/JP2021/005272 mailed Mar. 30, 2021 (with English Translation).
[cited by applicant]
Written Opinion of International Search Report issued in PCT /JP2021/005272 mailed Mar. 30, 2021 (with English Translation).
[cited by applicant]
Shang, et al, “Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma”, Gut 2021;70:1746-1757. doi:10.1136/gutjnl-2020-320716.
[cited by applicant]
Shang, et al, “Cabozantinib based combination therapy for the treatment of Hepatocellular Carcinoma”—Supplemental Material;
[cited by applicant]
Reference ID: 4375294. Highlights of Prescribing Information These highlights do not include all the information needed to use Cabometyx safely and effectively. See full prescribing information for Cabometyx.
[cited by applicant]
Loeuillard, “Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma”,
[cited by applicant]
Supplementary Methods—YAP Signature Differential Expression Analysis.
[cited by applicant]
Fujita, et al, High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells, PLOS ONE | DOI:10.1371…
[cited by applicant]
Yamada—“Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma”, BMC Cancer (2017) 17:334 DOI 10.1186/s12885-017-3324-3.
[cited by applicant]
Fujita, et al., High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115Concomitantly Suppresses Tumor Progression and BoneDestruction in Tumor-Induced Bone Disease Model withLung Carcinoma Cells, Published: Oct. 13, 2016…
[cited by applicant]
Pin Wu, et al., PD-L1 and Survival in Solid Tumors: A Meta-Analysis; PLOS ONE | DOI:10.1371/journal.pone.0131403 Jun. 26, 2015, 15 Pages.
[cited by applicant]
Ze-Jun Zhou, et al, PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis,
[cited by applicant]
Yaqi Li, et al, Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer, Molecular Cancer, (2016) 15:55, 15 pages.
[cited by applicant]
Jian Guan, MD, PhD, et al., Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade, Review Article, Arch Pathol Lab Med—vol. 141, Jun. 2017, 11 pages.
[cited by applicant]
Noah Frydenlund BS, MS, et al., PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies, Elsevier, Human Pathology, Jun. 2017; 21 pages.
[cited by applicant]
Ke Ma. et al. ,PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma, Oncology Letters 14: 250-256, 2017, 7 pages.
[cited by applicant]
Lulu Miao, et al., PD-L1 and c-MET expression and survival in patients with small cell lung cancer; Oncotarget, 2017, vol. 8, (No. 33), pp. 53978-53988, 11 pages.
[cited by applicant]
Runze Shang, et al, Cabozantinib based combination therapy for the treatment of Hepatocellular Carcinoma,
[cited by applicant]
Runze Shang, et al., Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma, Hepatology, Gut 2021;70:1746-1757. doi:10.1136/gutjnl-2020-320716, 12 pages.
[cited by applicant]
Dong Wang, et al. “Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review” Biology 2023, 12, 472, 17 pages.
[cited by applicant]
European Office Action issued in EP Application 18 854 415.9, on Sep. 18, 2024.
[cited by applicant]
European Office Action issued in EP Application 18 854 415.9, on Nov. 12, 2023.
[cited by applicant]
Response to Communication dated Dec. 12, 2023, filed on Jun. 7, 2024 in EP Application 18 854 415.9.
[cited by applicant]
Response to Communication dated May 19, 2021, filed on Oct. 11, 2021 in EP Application 18 854 415.9.
[cited by applicant]